Ali Asif

CIK 00019211631 companyNEWARK, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001921163

Recent Transactions

47 trades

Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-03-26−5,265→ 13,282 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-03-26−19,500→ 31,300 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-03-26$104.24/sh−24,765→ 60,753 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-03-26$12.17/sh+5,265→ 85,518 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-03-26$19.19/sh+19,500→ 80,253 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$12.17/sh+12,000→ 106,523 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$19.19/sh+16,000→ 94,523 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-27−12,000→ 18,547 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-27−16,000→ 50,800 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$83.14/sh−18,203→ 60,320 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-27$83.13/sh−28,000→ 78,523 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-20$82.48/sh−8,588→ 78,077 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2026-01-02+25,600→ 86,665 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2026-01-02+32,000→ 32,000 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-04-22$46.00/sh−1,756→ 61,065 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-12$12.17/sh+15,203→ 78,024 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-12$19.19/sh+9,700→ 87,724 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-03-12−15,203→ 30,547 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-03-12−9,700→ 66,800 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-03-12$58.73/sh−24,903→ 62,821 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-16−1,317→ 65,422 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-16−2,601→ 62,821 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2025-01-02+38,520→ 38,520 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2025-01-02+31,779→ 66,739 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-09-11$44.47/sh−12,000→ 34,960 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-09-11$12.17/sh+6,000→ 46,960 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-09-11$44.59/sh−2,203→ 34,960 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-09-11−6,000→ 76,500 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-09-11$19.19/sh+6,000→ 40,960 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-09-11−6,000→ 45,750 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-04-18$25.11/sh−1,234→ 37,163 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-03-01$32.33/sh−2,248→ 38,397 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-03-01−12,000→ 51,750 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-03-01$32.22/sh−12,000→ 40,645 total
Exercise/Conversion
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-03-01$12.17/sh+12,000→ 52,645 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-02-29$31.00/sh−2,089→ 40,645 total
Sale
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-02-29$30.61/sh−7,850→ 42,734 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-01-16$24.63/sh−1,452→ 50,584 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2024-01-02+78,000→ 78,000 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2024-01-02+21,000→ 52,036 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-05-31+12,000→ 35,186 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-05-31$26.07/sh−4,150→ 31,036 total
Tax Payment
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-04-18$23.21/sh−1,189→ 23,186 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2023-01-16+10,625→ 24,375 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2023-01-16+63,750→ 63,750 total
Award
Protagonist Therapeutics, Inc$PTGX
Common Stock
2022-04-18+13,750→ 13,750 total
Award
Protagonist Therapeutics, Inc$PTGX
Stock Option (right to buy)
2022-04-18+82,500→ 82,500 total

Companies

Protagonist Therapeutics, Inc
Chief Financial Officer
$PTGX

Recent Filings

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160

View on SEC.gov